Advanced

Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence.

Gunnarsson, Niklas; Sandin, Fredrik; Höglund, Martin; Stenke, Leif; Björkholm, Magnus; Lambe, Mats; Olsson-Strömberg, Ulla; Richter, Johan LU and Själander, Anders (2016) In European Journal of Haematology 97(4). p.387-392
Abstract
The clinical outcome for patients with chronic myeloid leukemia (CML) has improved dramatically following the introduction of tyrosine kinase inhibitors. An improved survival, combined with a constant incidence, is expected to increase the prevalence of CML. However, data on the prevalence of CML remain scarce. We examined the overall and relative (age and gender matched) survival and assessed the past, present and projected future prevalence of CML in Sweden. Data on all patients diagnosed with CML between 1970 and 2012 were retrieved from the Swedish Cancer Register and the Swedish Cause of Death Register. The five-year overall survival increased from 0.18 to 0.82, during the observed time period. Between 2006-2012 the five-year relative... (More)
The clinical outcome for patients with chronic myeloid leukemia (CML) has improved dramatically following the introduction of tyrosine kinase inhibitors. An improved survival, combined with a constant incidence, is expected to increase the prevalence of CML. However, data on the prevalence of CML remain scarce. We examined the overall and relative (age and gender matched) survival and assessed the past, present and projected future prevalence of CML in Sweden. Data on all patients diagnosed with CML between 1970 and 2012 were retrieved from the Swedish Cancer Register and the Swedish Cause of Death Register. The five-year overall survival increased from 0.18 to 0.82, during the observed time period. Between 2006-2012 the five-year relative survival was close to normal for 40-year-old, but considerably lower for 80-year-old CML patients (0.95 and 0.63, respectively). The observed prevalence tripled from 1985 to 2012: from 3.9 to 11.9 per 100,000 inhabitants. Assuming no further improvements in relative survival, the prevalence is projected to further increase by 2060 to 22.0 per 100,000 inhabitants (2,597 persons in Sweden). The projected dramatic increase in CML prevalence has major medical and health economic implications and needs to be considered in planning how to organize future care of CML patients. This article is protected by copyright. All rights reserved. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
European Journal of Haematology
volume
97
issue
4
pages
387 - 392
publisher
Wiley-Blackwell
external identifiers
  • pmid:26833713
  • scopus:84959299927
  • wos:000383698500011
ISSN
1600-0609
DOI
10.1111/ejh.12743
language
English
LU publication?
yes
id
0ad9432f-adcd-45f8-9645-117e88ccc9c3 (old id 8829523)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/26833713?dopt=Abstract
date added to LUP
2016-03-01 12:52:45
date last changed
2017-03-13 12:13:32
@article{0ad9432f-adcd-45f8-9645-117e88ccc9c3,
  abstract     = {The clinical outcome for patients with chronic myeloid leukemia (CML) has improved dramatically following the introduction of tyrosine kinase inhibitors. An improved survival, combined with a constant incidence, is expected to increase the prevalence of CML. However, data on the prevalence of CML remain scarce. We examined the overall and relative (age and gender matched) survival and assessed the past, present and projected future prevalence of CML in Sweden. Data on all patients diagnosed with CML between 1970 and 2012 were retrieved from the Swedish Cancer Register and the Swedish Cause of Death Register. The five-year overall survival increased from 0.18 to 0.82, during the observed time period. Between 2006-2012 the five-year relative survival was close to normal for 40-year-old, but considerably lower for 80-year-old CML patients (0.95 and 0.63, respectively). The observed prevalence tripled from 1985 to 2012: from 3.9 to 11.9 per 100,000 inhabitants. Assuming no further improvements in relative survival, the prevalence is projected to further increase by 2060 to 22.0 per 100,000 inhabitants (2,597 persons in Sweden). The projected dramatic increase in CML prevalence has major medical and health economic implications and needs to be considered in planning how to organize future care of CML patients. This article is protected by copyright. All rights reserved.},
  author       = {Gunnarsson, Niklas and Sandin, Fredrik and Höglund, Martin and Stenke, Leif and Björkholm, Magnus and Lambe, Mats and Olsson-Strömberg, Ulla and Richter, Johan and Själander, Anders},
  issn         = {1600-0609},
  language     = {eng},
  number       = {4},
  pages        = {387--392},
  publisher    = {Wiley-Blackwell},
  series       = {European Journal of Haematology},
  title        = {Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence.},
  url          = {http://dx.doi.org/10.1111/ejh.12743},
  volume       = {97},
  year         = {2016},
}